Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening

被引:11
|
作者
Zhou, Yeheng [1 ,2 ]
Peng, Jiale [1 ]
Li, Penghua [1 ]
Du, Haibo [1 ]
Li, Yaping [1 ]
Li, Yingying [1 ]
Zhang, Li [1 ]
Sun, Wei [2 ]
Liu, Xingyong [1 ]
Zuo, Zhili [1 ,2 ]
机构
[1] Sichuan Univ Sci & Engn, Sch Chem Engn, Zigong, Peoples R China
[2] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Ch, Kunming Inst Bot, Kunming, Yunnan, Peoples R China
关键词
IDO1; Molecular docking; HipHop pharmacophore; 3D-QSAR; PAINS; PHENYL BENZENESULFONYLHYDRAZIDES; THERAPEUTIC TARGET; CRYSTAL-STRUCTURES; DERIVATIVES; DOCKING; MECHANISM;
D O I
10.1016/j.compbiolchem.2018.11.024
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this study, a combination of virtual screening methods were utilized to identify novel potential indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. A series of IDOL potential inhibitors were identified by a combination of following steps: Lipinski's Rule of Five, Veber rules filter, molecular docking, HipHop pharmacophores, 3D-Quantitative structure activity relationship (3D-QSAR) studies and Pan-assay Interference Compounds (PAINS) filter. Three known categories of IDO1 inhibitors were used to constructed pharmacophores and 3D-QSAR models. Four point pharmacophores (RI-IDA) of IDOL inhibitors were generated from the training set. The 3D-QSAR models were obtained using partial least squares (PLS) analyze based on the docking conformation alignment from the training set. The leave-one-out correlation (q(2)) and non-cross-validated correlation coefficient (r(pred)(2)) of the best CoMFA model were 0.601 and 0.546, and the ones from the best CoMSIA model were 0.506 and 0.541, respectively. Six hits from Specs database were identified and analyzed to confirm their binding modes and key interactions to the amino acid residues in the protein. This work may provide novel backbones for new generation of inhibitors of IDOL.
引用
收藏
页码:306 / 316
页数:11
相关论文
共 50 条
  • [41] Novel candesartan derivatives as indoleamine 2,3-dioxygenase inhibitors
    Matsuno, Kenji
    Yamazaki, Hiroshi
    Isaka, Yoshinobu
    Takai, Kazushige
    Unno, Yuka
    Ogo, Naohisa
    Ishikawa, Yoshinobu
    Fujii, Satoshi
    Takikawa, Osamu
    Asai, Akira
    MEDCHEMCOMM, 2012, 3 (04) : 475 - 479
  • [42] Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors
    Cheng, Ming-Fu
    Hung, Ming-Shiu
    Song, Jen-Shin
    Lin, Shu-Yu
    Liao, Fang-Yu
    Wu, Mine-Hsine
    Hsiao, Wenchi
    Hsieh, Chia-Ling
    Wu, Jian-Sung
    Chao, Yu-Sheng
    Shih, Chuan
    Wu, Su-Ying
    Ueng, Shau-Hua
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (15) : 3403 - 3406
  • [43] Identification of potential indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors by an FBG-based 3D QSAR pharmacophore model
    Zhang, Lu
    Lai, Fangfang
    Chen, Xiaoguang
    Xiao, Zhiyan
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2020, 99
  • [44] Host cell depletion of tryptophan by IFNγ-induced Indoleamine 2,3-dioxygenase 1 (IDO1) inhibits lysosomal replication of Coxiella burnetii
    Ganesan, Sandhya
    Roy, Craig R.
    PLOS PATHOGENS, 2019, 15 (08)
  • [45] N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase
    Yang, Dan
    Zhang, Shengnan
    Fang, Xin
    Guo, Leilei
    Hu, Nan
    Guo, Zhanling
    Li, Xishuai
    Yang, Shuangshuang
    He, Jin Chao
    Kuang, Chunxiang
    Yang, Qing
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (20) : 9161 - 9174
  • [46] Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)
    Pan, Shulei
    Zhou, Yangli
    Wang, Qiusheng
    Wang, Yanlin
    Tian, Chenyu
    Wang, Tianqi
    Huang, Luyi
    Nan, Jinshan
    Li, Linli
    Yang, Shengyong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 207
  • [47] Research progress of indoleamine 2,3-dioxygenase inhibitors
    Jiang, Tianze
    Sun, Yingying
    Yin, Zhichao
    Feng, Sen
    Sun, Liping
    Li, Zhiyu
    FUTURE MEDICINAL CHEMISTRY, 2015, 7 (02) : 185 - 201
  • [48] Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays
    Huizhen Ge
    Longfei Mao
    Jie Zhao
    Yuwei Wang
    Danfeng Shi
    Xing Yang
    Xiaorui Wang
    Huanxiang Liu
    Xiaojun Yao
    Journal of Computer-Aided Molecular Design, 2021, 35 : 679 - 694
  • [49] Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen
    Smith, Jason R.
    Evans, Krystal J.
    Wright, Adam
    Willows, Robert D.
    Jamie, Joanne F.
    Griffith, Renate
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (03) : 1354 - 1363
  • [50] Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
    Nayak-Kapoor, Asha
    Hao, Zhonglin
    Sadek, Ramses
    Dobbins, Robin
    Marshall, Lisa
    Vahanian, Nicholas N.
    Ramsey, W. Jay
    Kennedy, Eugene
    Mautino, Mario R.
    Link, Charles J.
    Lin, Ray S.
    Royer-Joo, Stephanie
    Liang, Xiaorong
    Salphati, Laurent
    Morrissey, Kari M.
    Mahrus, Sami
    McCall, Bruce
    Pirzkall, Andrea
    Munn, David H.
    Janik, John E.
    Khleif, Samir N.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6